Mirixa Corporation Appoints Jim Vedder As SVP, Finance And Accounting

RESTON, Va., Feb. 17, 2015 /PRNewswire/ -- Mirixa Corporation, the leading provider of Medication Therapy Management (MTM) and other pharmacist-delivered patient care services for health plans, today announced the appointment of Jim Vedder as Senior Vice President of Finance and Accounting.

Mirixa Corporation logo.
Mr. Vedder is a certified public accountant with more than 23 years' experience in finance and accounting. Prior to joining Mirixa, he held a variety of key positions including, most recently, Chief Financial Officer of K12, Inc. Within his new role, Mr. Vedder will oversee all aspects of finance and accounting activities for Mirixa. A graduate of Indiana University of Pennsylvania, he earned a dual bachelor's degree in Finance and Accounting and is an active member of the American Institute of Certified Public Accountants (AICPA) and Financial Executives International.

"Jim is an experienced and talented financial expert with strong leadership skills and will be a valuable addition to Mirixa," states Marvin Richardson, Chief Executive Officer of Mirixa. "I am delighted to welcome him to the management team and look forward to working with him as we execute our new 3 year strategic plan."

"I am thrilled to join Mirixa. This is a company with tremendous capabilities and is a market leader within the pharmacy industry. I believe my skill set will be very complementary to the team as we continue to build and grow over the coming years," said Mr. Vedder.

Mr. Vedder will operate out of Mirixa's headquarters in Reston, VA.

About Mirixa

Mirixa Corporation, sponsored by the National Community Pharmacists Association (NCPA), is the leader in targeted patient care services delivered via the nation's largest pharmacy-based patient care network.  Dedicated to improving patients' health, Mirixa enables the health care community to deliver patient care services through retail pharmacy. The MirixaPro web-based clinical platform is used by pharmacists to deliver standardized patient care services.  For more information, please visit www.Mirixa.com.

Media Contacts:


Barbara Ellis


[email protected]

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.